.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
A pooled OCT biomarker analysis from the YOSEMITE and RHINE phase 3 trials examined how faricimab compared with aflibercept for anatomic disease control in diabetic macular edema. The analysis evaluated central subfield thickness and the presence or absence of intraretinal and subretinal fluid over time. Faricimab treatment produced sustained anatomic improvement, with higher proportions of eyes achieving important fluid-control endpoints at several study time points. These data complement visual-acuity outcomes by showing that anti-VEGF therapy can be assessed through multiple biologic and imaging markers rather than a single functional endpoint. For retina specialists, OCT remains central to deciding when to maintain, extend, or intensify treatment, and understanding how therapies influence persistent versus recurrent fluid can support more individualized follow-up. Importantly, anatomical improvement should still be interpreted alongside vision, diabetic control, treatment history, and structural sequelae. The publication highlights how modern DME management increasingly integrates functional and imaging outcomes to define durable disease control.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A pooled OCT biomarker analysis from the YOSEMITE and RHINE phase 3 trials examined how faricimab compared with aflibercept for anatomic disease control in diabetic macular edema. The analysis evaluated central subfield thickness and the presence or absence of intraretinal and subretinal fluid over time. Faricimab treatment produced sustained anatomic improvement, with higher proportions of eyes achieving important fluid-control endpoints at several study time points. These data complement visual-acuity outcomes by showing that anti-VEGF therapy can be assessed through multiple biologic and imaging markers rather than a single functional endpoint. For retina specialists, OCT remains central to deciding when to maintain, extend, or intensify treatment, and understanding how therapies influence persistent versus recurrent fluid can support more individualized follow-up. Importantly, anatomical improvement should still be interpreted alongside vision, diabetic control, treatment history, and structural sequelae. The publication highlights how modern DME management increasingly integrates functional and imaging outcomes to define durable disease control.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
